Peer Reviewed
Drug update

Pramipexole for Parkinson’s disease

Kaitlyn L Parratt, Mariese Hely, Victor Sc Fung
Abstract
Pramipexole (Sifrol) is a highly potent dopaminergic drug that is useful for the treatment of both early and mid-to-late stage Parkinson’s disease.
Key Points
    What is pramipexole?

    Pramipexole (Sifrol) is a nonergoline dopamine agonist that was PBS listed (restricted benefit) on 1 June 2008 as adjunctive treatment for patients with Parkinson’s disease who are treated with levodopa–decarboxylase inhibitor combinations. Pramipexole has Therapeutic Goods Administration (TGA) approval for use as monotherapy and adjunctive therapy with levodopa for Parkinson’s disease. Pramipexole is also TGA approved for the symptomatic treatment of restless legs syndrome.

Get full access
Subscribe for full access to all articles
Buy this article

Single article purchases are temporarily unavailable due to site maintenance.

If you would like to purchase an article during this time, please email us at [email protected] with the article details and we'll assist you directly. We'll also let you know when online purchasing is available again.

Thank you for your patience and understanding.

Already a subscriber?